Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs

Diabetologia

Volumn 54, Issue 8, 2011, Pages 2206-2208

  Hjollund K R ^a   Deacon, C F ^a   Holst, J J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Animals; Dipeptidyl peptidase 4; Dipeptidyl peptidase 4 inhibitors; GLP 1; Incretin enhancers; Incretins; Pharmacokinetics; Swine; Vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; NEUROMEDIN C; VILDAGLIPTIN;

ANTIHYPERGLYCEMIC ACTIVITY; AREA UNDER THE CURVE; DRUG ACTIVITY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; INTESTINE SECRETION; LETTER; LIVER LEVEL; NONHUMAN; PERIPHERAL VEIN; PRIORITY JOURNAL; SWINE;

ADAMANTANE; ANIMALS; BOMBESIN; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; NITRILES; PEPTIDE FRAGMENTS; PORTAL VEIN; PYRROLIDINES; SWINE;

EID: 79960900778     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2168-7     Document Type: Letter

References (8)

1. Hansen L, Deacon CF, Orskov C, Holst JJ (1999) Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356-5363
2. Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminallytruncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957
3. Holst JJ, Vilsboll T, Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127-136
4. Simonsen L, Pilgaard S, Carr RD, Kanstrup AB, Holst JJ, Deacon CF (2009) Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto-Kakizaki rats. Horm Metab Res 41:851-853
5. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271:E458-E464
6. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA (2000) Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 49:611-617 (Pubitemid 30183750)
7. Zander M, Christiansen A, Madsbad S, Holst JJ (2004) Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care 27:1910-1914 (Pubitemid 38989231)
8. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ (2002) Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172:355-362 (Pubitemid 34183084)